Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2′-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide–Triantenarry N-Acetyl-galactosamine Conjugate that Targets the Human Transmembrane Protease Serine 6-Reference-Cited by-同舟云学术

Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2′-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide–Triantenarry N-Acetyl-galactosamine Conjugate that Targets the Human Transmembrane Protease Serine 6

Published:2021-01-11 Issue:1 Volume:377 Page:51-63
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Zanardi Thomas A.,Korbmacher Birgit,Boone Laura,Engelhardt Jeffrey A.,Wang Yanfeng,Burel Sebastien,Prill Bobby,Aghajan Mariam,Guo Shuling,Henry Scott P.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference34 articles.

1. Structural Requirements for Cationic Lipid Mediated Phosphorothioate Oligonucleotides Delivery to Cells in Culture

2. Crooke S (2008) Antisense Drug Technology: Principles, Strategies, and Applications, 2nd ed, Taylor & Francis Group, Boca Raton, FL.

3. Integrated safety assessment of 2′-O-methoxyethyl chimeric antisense oligonucleotides in NonHuman primates and healthy human volunteers;Crooke;Mol Ther,2016

4. Integrated assessment of the clinical performance of GalNAc3-conjugated 2′-O-methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience;Crooke;Nucleic Acid Ther,2019

5. RNA-Targeted Therapeutics

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoferremia of inflammation: Innate host defense against infections;Blood Cells, Molecules, and Diseases;2024-01

2. Overview of the Nonclinical Development Strategies and Class Effects of Oligonucleotide-based Therapeutics;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

3. Top advances of the year: Myeloproliferative neoplasms;Cancer;2023-09-28

4. TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis;Advances in Therapy;2023-01-23

5. Directing the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery;Pharmaceutical Research;2022-09-15